Smart for Life (SMFL) Announces 59% Increase in Revenues, Year-Over-Year

New Report Coming, Sign up to our Newsletter for Priority Notification. Absolutely banging numbers, we view Smart...

Smart for Life (SMFL) Reports, Headlines and More.

Smart For Life Corporate Investor Center 2022, 28-11. ($0.40) Smart for Life (SMFL) Announces...

Cosmos Health (COSM) and Smart for Life (SMFL) Execute Letter of Intent for Strategic...

LOI Calls for the Provision of SMFL Pan-European Access and COSM North American Access for Products and Services MIAMI...

Smart For Life (SMFL) $0.37 Announces Initiation of Equity Analyst Coverage by Dawson James...

Initiates with “Buy” recommendation and $8 price target. MIAMI, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Smart for Life,...

Smart for Life (SMFL) Announces Letter of Intent to Acquire Largest Acquisition to Date.

6th Acquisition to Date is Expected to Add over $15 million of Revenue and to be Accretive to Earnings.

DCS (DCSX) Announces Closing of Fully Subscribed USD $1.5 Million Private Placement Financing.

San Diego, California--(Newsfile Corp. - September 9, 2022) - Direct Communication Solutions, Inc. (OTCQX: DCSX) (CSE: DCSI) (FSE: 7QU), a leading provider of...

OnFolio Holdings Inc. (ONFO) Announces Pricing of $13.7 Million Initial Public Offering and Nasdaq...

Nice work by EF Hutton. We like this business model. Similar to old school incubator, but they acquire rather than invest and...

Smart for Life (SMFL) Capitulates?

We Are Long Term Bullish on Smart for Life. After a Volatile Post IPO Trading, we may Have Seen the Bottom....

Smart for Life (SMFL) $0.43 on Track to Close Pending Acquisition of Ceautamed Worldwide.

Has Smart for Life Found a Base at $0.45? Market Action Aside, We Think So. Report Out Monday.

Smart for Life (SMFL) Teams up With Diamond Creek Capital

IPO Buyers Liked it at $5.00. We Liked it at $0.85. We Love it at $0.55. LIVE...

Latest article

Adding Citius Pharma (CTXR) $0.66 to 2024 Watch List.

Three Years Since we Last Added Citius (CTXR) to the Watch List, and it Looks Better Than Ever!

Citius Pharmaceuticals (CTXR) Prospectus, Powerpoint & Fact Sheet.

CRANFORD, N.J., April 26, 2024 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and commercialization...

GeoVax (GOVX) Launches Vaccine Manufacturing System.

GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System Manufacturing Process for Phase 3 and Commercial Production...